Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about the availability of the research chemical GT20029 for hair loss treatment and when companies like Anageninc will have it. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

A user reported that after experiencing hair thinning, they started using finasteride in 2024 and later began GHK-Cu peptide injections in March 2026, which they believe stopped their hair loss and made their hair feel thicker. The user shared their experience despite receiving criticism for not solely endorsing finasteride.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

RU58841 caused severe side effects like heart palpitations and shortness of breath, leading the user to stop using it. Minoxidil and finasteride were effective without side effects, while RU58841's safety and effectiveness remain uncertain.

The user is considering adding RU58841 to liquid minoxidil without propylene glycol (PG) due to an allergy and is asking if this combination is effective and if PG is necessary. They have been using finasteride and minoxidil foam, plan to use RU58841 with liquid minoxidil in the evening, and continue finasteride.

The conversation discusses the potential of cinnamic acid for hair growth. It also mentions treatments like Minoxidil, finasteride, and RU58841.

Intermittent fasting may inhibit hair growth by triggering a stress response that affects hair-follicle stem cells. Some users believe genetics and DHT play a larger role in hair loss, and treatments like Minoxidil and Finasteride are mentioned as ineffective for some.

The user is using topical finasteride, Bioscalin, Omega 3, and hair filler therapy for hair loss. There is some progress noted, but varying photo angles and lighting make it hard to assess fully.

The conversation discusses hair loss linked to BDNF-increasing nootropics like Semax and Lions Mane. Suggested topical treatments include capsaicin, beta-glucan, and ginseng to counteract TGF-B activation.

MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.

The user is experiencing a greasy and dandruff-prone scalp from using RU58841 with glycerin and is seeking alternative carriers for seborrheic dermatitis. They are also using dutasteride 0.5mg.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. Concerns are raised about the lack of studies on RU58841 and its potential effects.

The conversation discusses a video about GT20029, a treatment for hair loss, and its comparison to KX826. Users express interest in the video's effectiveness and potential, and praise its informative content.

The user is allergic to minoxidil and plans to try Redensyl hair serum and derma rolling for hair regrowth. They cannot start finasteride until age 18.

The conversation is about comparing keratin hair fibers to Gossypium Herbaceum hair fibers for diffuse hair loss. The user prefers keratin fibers for their durability and is seeking a bulk purchase option.

The conversation discusses concerns about using a high concentration of 1% topical finasteride for hairline balding, with some users suggesting starting with a lower dose. It also mentions the use of GHK-CU peptide and the importance of considering the formulation to avoid excessive absorption.

A 23-year-old male experienced nipple sensitivity after starting finasteride for hair loss and stopped using it due to concerns about gynecomastia. He is worried about the risk of developing gynecomastia if he resumes finasteride, especially with plans to increase muscle mass.

The user has been using oral finasteride for over a year and recently added GHK-CU for two months, seeing progress but seeking further improvement, especially on the hairline. They discuss sourcing GHK-CU, its effects, and the importance of third-party testing, while considering additional treatments like dutasteride and hair transplants for better results.

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.

The user is seeking help with using Ell-Cranell for hair loss treatment. They are unsure about the correct application method and dosage. They also inquire about combining microneedling with topical alfatradiol and question a study that referred to alfatradiol as a hair growth inhibitor in male mice.

Treatments for hair loss, specifically discussing the use of RU58841 and Pyrilutamide from Actifolic. The poster is inquiring about experiences with these products and results.

A 24-year-old with hair thinning is using a regimen including dutasteride, RU58841, HGH, GHK-cu, and other compounds to protect and regrow hair. They are also incorporating a mild cutting cycle with testosterone propionate, anavar, and tirzepatide.

A user named "LordGeek101" shared their positive experience with hair regrowth after using 5mg of finasteride daily, 5% minoxidil twice daily, and hormone replacement therapy (HRT) for 8 months. The user is transgender (MTF) and mentioned that the larger dose of finasteride was recommended by their doctor for better chances of hair revival.

Hair loss is linked to scalp fibrosis and tension, which result from chronic mechanical stress and androgenic signaling. Treatments include blocking androgens with finasteride, promoting hair growth with topical minoxidil, and improving scalp mobility through exercises.

The FDA warned that topical finasteride can cause serious side effects like sexual dysfunction and brain fog, similar to oral finasteride. Compounded topical formulations pose additional risks due to lack of regulation.

The conversation is about the anticipation and uncertainty regarding the release of GT20029 Phase 2 results for hair loss treatment. Users express hope for its effectiveness and minimal side effects compared to other treatments like Pyri and HMI115.

Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.

A user's experience with hair loss and scalp inflammation, which was alleviated by using RU58841 along with finasteride and dutasteride. A theory of inflammation possibly being a cause of hairloss is also discussed.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.

PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.